

pmi

PHARMA SUMMIT 23

PARTNERING TO IMPROVE
HUMAN HEALTH




Adrian Coyle,
Access & Strategic
Partnerships Manager



Proudly supported by:





Public-Private Partnerships (PPP): Partnering on mission-driven initiatives across Europe



Pharma Summit 2023: Partnering to Improve Human Health

30th March 2023

Adrian Coyle, Access and Strategic Partnership Manager

Takeda Products Ireland Ltd.

Public-Private Partnerships

PPP Overview





What is a  **Public Private** Partnership?

PATIENT COMMUNITIES

LIFE SCIENCES INDUSTRY

- Pharma
- Medical device
- Biotechnology
- Small and Medium Enterprises

GOVERNMENT AGENCIES

- Regulatory Agencies
- Health Technology Assessments (HTA)
- Payers
- Funding Agencies

Public-Private Partnership (PPP):

Pre-competitive, mission-driven alliances between public, private and non-profit entities to leverage resources and expertise toward the advancement of health care and benefits for patients. Members – united by a shared purpose - typically pool responsibilities, risks, and decision-making, while gaining access to joint resources, knowledge, and mutually beneficial outcomes.

OTHER INDUSTRY

- Technology companies
- Consumer products

ACADEMIC & RESEARCH INSTITUTES

- Key Opinion Leaders
- Subject Matter Experts

NON-PROFIT ORGANIZATIONS




Public-Private Partnership (PPP):

**Pre-competitive, mission-driven
alliances between public,
private and non-profit entities**


to leverage resources and expertise toward the advancement of health care and benefits for patients. Members – united by a shared purpose - typically pool responsibilities, risks, and decision-making, while gaining access to joint resources, knowledge, and mutually beneficial outcomes.




Innovative Medicines Initiative (IMI) brought a decade of successful public private partnerships¹



The partnership worked to improve health by speeding up development and access to innovative medicines



Supports collaboration between the key players involved in health research from public and private sectors



Significant outputs from research and innovation that benefit from greater co-ordination and knowledge sharing

IMI working to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or societal need

Significant IMI projects in many areas; highlighting some projects from paediatrics, digital/data and antibiotics



Implementation of multi-national paediatric clinical trials via new networks across 20 countries²



17 consortia targeting big data and digital to drive innovation in healthcare, standardising data collection and ensuring ethical data conduct⁴



7 new drugs under development to address priority pathogens with novel treatments⁶

Making a difference to **PAEDIATRIC** diseases

Benefiting from **DIGITAL** healthcare solutions

Ensuring **ANTIBIOTICS** remain effective

Tackling paediatric cancers by developing preclinical tumour models testing to speed-up regulatory filings³


Building a federated data network of 100 million citizens, haematological health database, blockchain health data for trials and supply chain⁵

Anti-microbial resistance (AMR) key focus with AMR Accelerator taking a 360 approach to tackling resistance⁷


There is a paradigm shift to innovative health



From disease care to health care and learning healthcare systems, with the citizen/patient at the centre



The Innovative Health Initiative has FIVE areas of action, via a Cross-Sector Partnership with a potential €2.4B public private partnership^{8,9}



8. Innovative Medicines Initiative funding model, <https://www.ih.europa.eu/about-ih/ih-funding-mode>, accessed on 23rd of March 2023;

9. Horizon Europe, Innovative Health Initiative (IHI), <https://horizoneurope.eu/global-challenges-european-industrial-competitiveness/health/innovative-health-initiative>, accessed on 23rd March 2023

Takeda is an aspiring

LEADER

in Public-Private
Partnerships









76

Countries⁹



Summary of Irish involvement in PPPs involving Takeda⁹



Ongoing PPPs at Takeda

96



Irish involvement

10

8 Rep of Ireland
2 involve Northern Ireland



Irish Organisations
involved

7



Types of Projects

- Rare Disease Diagnosis
- Digital Endpoints
mobility/Fatigue
- Patient Adherence
- Mechanisms of non-response
to treatments
- Safety Monitoring
- Disease specific initiatives

H2O Health Outcomes Observatory¹⁰



The mission of H2O is

“to empower patients with tools to monitor their outcomes independently, to promote the use of their outcomes in decision making with clinicians, to create transparency of outcomes to facilitate value-based healthcare models and to create an ethical governance model for patient-reported health data in the interest of patients, science and society”.

H2O will equip patients with tools to measure their outcomes in a standardised way, whilst giving them full control of their data.

KEY FACTS



23
Partners



EUR 21_m
Budget



2020 - 2025
5 YR
Duration

Creating ‘health outcomes observatories’ that will amplify the patient voice both in their own healthcare and in healthcare systems more broadly



Takeda is the overall lead on this project

abbvie



SCREEN4CARE¹¹




SCREEN4CARE aims to

“identify existing resources and initiatives that can be used for the large-scale cross-sector ecosystem, including European-wide data sources amenable for Machine Learning, regulatory frameworks, ethical considerations and business considerations in the field of newborn screening (NBS) and digital technologies for Rare Disease (RD) diagnosis.”

SCREEN4CARE will develop two approaches:

- Newborn Screening (NBS)
- Multiple digital projects to accelerate diagnosis



Shorten the path to Rare Disease diagnosis via Newborn genetic screening and the application of advanced digital technologies.



Takeda colleagues have key Project Leadership roles



KEY FACTS



39
Partners



EUR 25m
Budget



2021 - 2026
5 YR
Duration

11. Screen4Care, <https://screen4care.eu/>, accessed on March 23rd 2023

Thank you



pmi

PHARMA SUMMIT 23

PARTNERING TO IMPROVE HUMAN HEALTH

Proudly supported by:

